Folic acid and prevention of anomalies of fœtal neural tube closing in women treated for epilepsy;Acide folique et prévention des anomalies de fermeture du tube neural chez la femme épileptique traitée

Revue Neurologique

Volumn 159, Issue 2, 2003, Pages 165-170

  Weber, M ^a   Dib, M ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FOLIC ACID; VALPROIC ACID;

BRAIN DEVELOPMENT; CONCEPTION; CONGENITAL MALFORMATION; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; EPILEPSY; FEMALE; FETUS; FOLIC ACID DEFICIENCY; GESTATIONAL AGE; HUMAN; NEURAL TUBE DEFECT; ORGANOGENESIS; PRACTICE GUIDELINE; PREGNANCY; REVIEW; TREATMENT INDICATION;

ADULT; ANTICONVULSANTS; EPILEPSY; FEMALE; FOLIC ACID; HUMANS; INFANT, NEWBORN; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0037291966     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. AUBARD Y, PIVER P, CHINCILLA AM, BAUDET JH. (1997). Folate and neural tube: A review. J Gynecol Obstet Biol Reprod, 26: 576-584.
2. BAXTER MG, MILLAR AA, WEBSTER RA. (1973). Some studies on the convulsant action of folic acid. Br J Pharmacol, 48: 350-1.
3. BERRY RJ, LI Z, ERICKSON JD, et al. pour le China-US. (1999). Collaborative Project for Neural Tube Defect Prevention. Prevention of neural-tube defects with folic acid in China. New Eng J Med 341: 1485-1490.
4. BIALE Y, LEWENTHAL H. (1984). Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Clin Obstet Gynecol Reprod Biol, 18: 211-216.
5. BOLTON KING P, LIE RT, IRGENS LM. (1996). Spina bifida and cleft lip among newborns of Norwegian women with epilepsy: changes related to the use of anticonvulsivants. Am J Public Health, 86: 1454-1456.
6. BOWER C, STANLEY FJ. (1989). Dietary folate as a risk factor for neural tube defects: evidence from a case-control study in Westrern Australia. Med J Aust, 150: 613-619.
7. BOWER C. (1994). Epilepsy in pregnancy: Neural tube defects and folate. Med J Aust, 160: 56-57.
8. BUNDUKI V, DOMMERGUES M, ZITTOUN J, et al. (1995). Maternal fetal folate status and neural tube defects: a case control study. Biol Neonate, 67: 154-159.
9. BUTTERWORTH CE, BENDICH A. (1996). Folic acid and the prevention of birth defects. Annu Rev Nutr, 16: 73-97.
10. CAMPBELL. (1996). How safe are folic acid supplements? Arch Intern Med, 156: 1638-1644.
11. CHAMPEL V, RADAL M, MOULIN-VALLZA M, JONVILLE-BERA AO, AUTRET LECA E. (1999). Faut-il prescrire de l'acide folique aux femmes traitées par acide valproïque et/ou carbamazépine. Rev Neurol, 155: 220-224.
12. COMITÉ DE NUTRITION. SOCIÉTÉ FRANÇAISE DE PÉDIATRIE. (1995). « Acide folique et grossesse ». Arch Fr Ped, 2: 173-181.
13. CZEIZEL AR, DUDAS I. (1992). Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. New Eng J Med, 327: 1832-1835.
14. DALY LE, KIRKE PNB, MOLLOY A, WEIR DG, SCOTT JM. (1995). Folate levels and neural tube defects. JAMA, 174: 1698-1702.
15. DANSKY LV, ANDERMANN E, ROSENBLATT D, et al. (1987). Anticonvulsants, folate levels and pregnancy outcome: a prospective study. Ann Neurol, 21: 176-182.
16. DAWSON EB, EVANS DR, VAN HOOK JW. (1998). Amniotic fluid B12 and folate levels associated with neural tube defects. Am J Perinatol, 15: 511-514.
17. DELGADO-ESCUETA AV, JANZ (1992). Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology, 42: 149-160.
18. DOLK H, SELLER MJ. (1993). Neural tube defects: A survey of lesion descriptions made by different European pathologists. J Med Genet, 30: 942-946.
19. DUNCAN S, MERMCHO S, LOPES-CENDES I, et al. (2001). Repeated neural tube defects and valprate monotherapy suggest a pharmacological abnormality. Epilepsia, 42: 750-753.
20. ELEFANT E, MIGNOT G. (1995). Grossesse: acide folique et prévention des anomalies du tube neural. La revue Prescrire, 15: 757-764.
21. FAVIER A, FAVIER M. (1991). Place de la carence en zinc dans l'étiologie des malformations du tube neural. Rev Fr Gynecol Obst, 86: 49-55.
22. GIBBERD FB, NICHOLLS A, WRIGHT MG. (1981). The influence of folic acid on the frequency of epileptic attacks. Eur J Clin Pharmacol, 19: 57-60.
23. GOETSCH C. (1962). An evaluation of aminopterin as an abortifacient. Am J Obstet Gynecol, 89: 532-534.
24. HALL JG, SOLEHDIN F. (1998). Genetics of neural tube defects. Ment Retard Dev Disabil Res Rev, 4: 269-281.
25. HERNANDEZ-DIAZ S, WERLER MM, WALKER AM, MITCHELL AA. (2000). Folic acid antagonists during pregnancy and the risk of birth defects. New Engl J Med, 343: 1608-1614.
26. HIBBARD ED, SMITHELLS WN. (1965). Folic acid metabolism and human embryopathy. Lancet, 1: 1254-1255.
27. e edit., Pergamon Press, 1277-1310.
28. JANZ D. (1994). Are antiepileptic drugs harmful when taken during pregnancy? J Perinat Med, 22: 367-375.
29. KIRKE PN, MOLLOY AM, DALY LE, BURKE H, WEIR DG, SCOTT JM (1993). Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med, 36: 703-708.
30. LAURENCE KM, JAMES N, MILLER MH et al. (1981). Double-blind randomised controlled trial of folate treatment before conception to prevent recurrences of neural-tube defects. BMJ, 282: 1509-1511.
31. LEWIS DP, VAN DYKE DC, STUMBO PJ, BERG MJ. (1998). Drug and environmental factors associated with adverse pregnancy outcomes Part II: improvement with folic acid. Ann Pharmacother, 32: 947-961.
32. LINDHOUT D. (1992). Pharmacogenetics and drug interactions: role in antiepileptic drug-induced teratogenesis. Neurology, 42: Suppl 5, S43-S47.
33. LINDHOUT D, OMTZIG JGC. (1994). Teratogenic effects of antiepileptic drugs: Implications for the management of epilepsy in women of chilbearing age. Epilepsia, 35: S19-S28.
34. LOCKSMITH GJ, DUFF P. (1998). Preventing neural tube defects: The importance of periconceptional folic acid supplements. Obstet Gynecol, 91: 1027-1034.
35. MEADOW SR. (1968). Anticonvulsant drugs and congenital abnormalities. Lancet, 2, 1396.
36. MILLS JL, THOADS GG, SIMPSON JL, et al. (1989). The absence of a relation between the periconceptional use of vitamins and neural tube defects. New Eng J Med, 121: 430-435.
37. MILLS JL, MCPARTLIN JM, KIRKE PN, LEE YJ, CONLEY MR, WEIR DJ, SCOTT JM. (1995). Homocystein metabolism in pregnancies complicated by neural-tube defects. Lancet, 345: 149-151.
38. MILUNSKY A, JICK H, JICK S, et al. (1989). Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA, 262: 2847-2852.
39. MORRELL MJ. (1998). Guidelines for the care of women with epilepsy. Neurology, 51: S21-S27.
40. MRC (1991). Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet, 338: 131-7.
41. ORGAWA Y, KANEKO S, OTANI K, FUKUSHIMA Y. (1991). Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res, 8: 75-78.
42. OGUNI M, DANSKY L, ANDERMANN E, SHERWIN A, ANDERMANN F. (1992). Improved pregnancy outcome in epilepticc women in the last decade: relationship to maternal anticonvulsant therapy. Brain Develop, 14: 371-380.
43. OLNEY R, MULINARE J. (1998) J. Epidemiology of neural tube defects. Ment Retard Dev Disabil Res Rev, 4: 241-246.
44. RALSTON AJ, SNAITH RP, HINLEY JB. (1970). Effects of folicc acid on fit-frequency and behaviour in epileptics on anticonvulsants. Lancet, 1: 867-868.
45. REYNOLDS EH. (1966). Anticonvulsant therapy, megaloblastic haematopoiesis and folic acid metabolisme. Q J Med, 35: 521-37.
46. ROBERT E, ROBERT JM, LAPRAS C. (1983). L'acide valproique est-il tératogène? Rev Neurol, 139: 445-447.
47. ROSA FW. (1991). Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med, 324: 674-677.
48. SMITHELLS RW, SHEPPARD S, WILD J, SCHORAH CJ. (1989). Prevention of neural tube defect recurrences in Yorshire: final report. Lancet, 2: 489-499.
49. SMITHELLS RW, SHEPPARD S, WILD J, SCHORAH CJ. (1976). Nutritional deficiencies and neural tune defects. Arch Dis Child, 51: 944-950.
50. STEEGERS-THEUNISSEN RP, BOERS GH, NIJHUIS JG, THOMAS CM, BORM GF, ESKES TK. (1995). Neural tube defects and elevated homocystein levels in amniotic fluid. Am J Obstet Gynecol, 172: 1436-1441.
51. THORAND B, PIETRZIK K, PRINZ-LANGENOHL R, HAGES M, HOLZGREVE W. (1996). Maternal and foetal serum and red blood cell folate and vitamin B12 concentrations in pregnancies affected by neural tube defects. Z Geburtshilfe Neonatol, 200: 176-180.
52. VERGEL RG, SANCHEZ LR, DEREDERO BL, et al. (1990). Primary prevention of neural tube defects with folic acid supplementation. Cuban experience. Prenat Diagn, 10: 149-152.
53. WEBER M. (1987). Medicaments anti-épileptiques et tératogénèse. Rev Neurol, 143: 413-419.
54. WEBER M. (1992). Monothérapie ou polythérapie chez la femme en âge de procréer. Epilepsies, 4: 119-124.
55. WERLER M, SHAPIRO S, MITCHELL A. (1993). Periconceptional folic acid exposure and risk of occurrent neural tube defects. Jama, 269: 1257-1261.
56. ZAHN CA, MORRELL MJ, COLLINS SD, LABINER DM, YERBY MS. (1998). Management issues for women with epilepsy: A review of the literature. Neurology, 51: 949-956.
57. ZHU M, ZHOU S. (1989). Reduction of the teratogenic effects of phenytoin by folic acid and a mixture of folic acid, vitamins and amino acids: a preliminary trial. Epilepsia, 30: 246-251.